Research Use Only (RUO): All products are sold exclusively for in vitro research. Products must not be used in human or animal trials, administered to humans or animals, or supplied to any third party for human investigational use.
CJC-1295 no DAC
Tested For:
Purity Weight TFA Free STERILITY ENDOTOXINS(LPS) HEAVY METALS
View Lab Reports
CJC-1295 without DAC, also identified in the research literature as Mod GRF 1-29, is a 29-amino-acid synthetic analog (also referred to as an analog) of growth hormone-releasing hormone (GHRH). Four targeted amino acid substitutions at positions 2, 8, 15, and 27 give CJC-1295 strong resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), extending its functional half-life well beyond that of native GHRH while preserving the short-acting, pulsatile release profile that distinguishes it from the DAC-conjugated variant. (1,2) Preclinical and human pharmacokinetic data show dose-dependent increases in both growth hormone (GH) and insulin-like growth factor 1 (IGF-1) following subcutaneous administration. (3) Every batch of CJC-1295 no DAC from Healius Peptides is manufactured to >99% purity and verified through independent third-party HPLC and mass spectrometry testing, with a full Certificate of Analysis available for every lot. View our full testing methodology on the Healius Lab Testing page. For research use only.
Original price was: $64.95.Current price is: $54.95.
Peptides are sold as lyophilized (powder) to ensure stability and purity
Original price was: $64.95.Current price is: $54.95.
1 in stock
Buy 1
$54.95
Total:
$54.95
Buy 3 and save 5%
$54.95
$52.20
Total:
Buy 5 and save 10%
$54.95
$49.46
Total:
Buy 10+ and save 15%
$54.95
$46.71
Total:
What is CJC-1295 no DAC (Mod GRF 1-29)
CJC-1295 without DAC, also identified in the research literature as Mod GRF 1-29, is a 29-amino-acid synthetic analog (also referred to as an analog) of growth hormone-releasing hormone (GHRH). Four targeted amino acid substitutions at positions 2, 8, 15, and 27 give CJC-1295 strong resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), extending its functional half-life well beyond that of native GHRH while preserving the short-acting, pulsatile release profile that distinguishes it from the DAC-conjugated variant. (1,2) Preclinical and human pharmacokinetic data show dose-dependent increases in both growth hormone (GH) and insulin-like growth factor 1 (IGF-1) following subcutaneous administration. (3) Every batch of CJC-1295 no DAC from Healius Peptides is manufactured to >99% purity and verified through independent third-party HPLC and mass spectrometry testing, with a full Certificate of Analysis available for every lot. View our full testing methodology on the Healius Lab Testing page. For research use only.
What is CJC-1295 no DAC (Mod GRF 1-29)?
CJC-1295 no DAC is a tetrasubstituted synthetic peptide based on the first 29 amino acids of human growth hormone-releasing hormone. Native GHRH contains 44 amino acids, but early truncation studies established that the biological activity required for receptor binding resides almost entirely within the N-terminal 1-29 fragment. (1) That truncated sequence, known as GRF (1-29) or sermorelin, became the structural starting point for CJC-1295.
The limitation of unmodified GRF (1-29) is rapid enzymatic breakdown. DPP-IV cleaves the peptide bond between positions 2 and 3 within minutes of entering the bloodstream, rendering the molecule inactive before it can exert a meaningful effect on pituitary somatotrophs. (2) CJC-1295, no DAC, overcomes this through four specific amino acid substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes protect the DPP-IV cleavage site, reduce oxidative susceptibility during synthesis and storage, and increase binding affinity at the GHRH receptor. (1,4)
The nomenclature around this peptide causes frequent confusion. The original CJC-1295, developed by ConjuChem Biotechnologies, included a Drug Affinity Complex (DAC), a maleimidopropionic acid linker attached to a C-terminal lysine residue that binds serum albumin in vivo, thereby extending the circulating half-life to approximately 6 to 8 days. (3) CJC-1295 “no DAC” or “without DAC” removes this albumin-binding modification entirely, resulting in a short-acting peptide with a half-life of roughly 30 minutes. (5) In the research peptide market, this compound is frequently sold under the name Mod GRF 1-29, which is the technically accurate descriptor for the tetrasubstituted GRF (1-29) analog without DAC conjugation. All three names, CJC-1295 no DAC, CJC-1295 without DAC, and Mod GRF 1-29, refer to the same 29-amino-acid sequence with the molecular formula C152H252N44O42 and a molar mass of 3,367.9 g/mol. (4)
How Does CJC-1295 Work? Mechanism of Action
CJC-1295 activates the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary gland. (1) Binding triggers a well-characterized (also characterized) Gs-mediated signaling (also known as signaling) cascade: adenylyl cyclase activity increases, intracellular cyclic AMP (cAMP) concentrations rise, and protein kinase A (PKA) phosphorylation events follow. This cascade drives transcription of the GH-1 gene, synthesis of growth hormone protein, and exocytotic release of GH-containing secretory granules into the systemic circulation. (6)
The critical distinction between CJC-1295 no DAC and exogenous recombinant growth hormone (rhGH) lies in how GH enters the bloodstream. Exogenous rhGH produces a flat, non-physiological elevation. CJC-1295, no DAC, because of its short half-life, generates a discrete pulse of GH release that mirrors the body’s endogenous ultradian rhythm. Growth hormone is normally secreted in pulses, with the largest amplitude surges occurring during slow-wave sleep and immediately following intense physical exertion. (7) By stimulating the pituitary to release its own stored GH rather than replacing it with an external source, CJC-1295 no DAC preserves the negative feedback loops that regulate the GH-IGF-1 axis, including somatostatin-mediated inhibition between pulses. (1,6)
Downstream of GH release, the liver responds by producing IGF-1, the primary effector molecule responsible for many of GH’s anabolic and metabolic effects. Published pharmacokinetic data from human trials of CJC-1295 (with DAC) demonstrated dose-dependent IGF-1 elevations sustained for 9 to 11 days after a single injection. (3) While the no-DAC variant produces shorter GH peaks, repeated pulsatile administration has been shown in animal models to normalize (also spelled normalize) GH output and restore growth velocity in GHRH-deficient mice to levels comparable with daily exogenous GH injection. (8)
CJC-1295 Benefits: What Does the Research Show?
Research into CJC-1295 and its related GHRH analogs spans more than two decades of preclinical investigation and early-phase human trials. The primary areas of interest center on GH axis amplification, body composition, tissue repair, sleep architecture, and metabolic parameters.
Growth Hormone and IGF-1 Amplification
The most directly measured effect of CJC-1295 is its capacity to elevate circulating GH and IGF-1. In the pivotal Teichman et al. (2006) human pharmacokinetic study, healthy adult subjects receiving subcutaneous CJC-1295 (with DAC) showed GH increases of 2- to 10-fold above baseline for 6 or more days, and IGF-1 elevations of 1.5- to 3-fold persisting for 9 to 11 days after a single dose. (3) Repeated dosing produced a cumulative effect, with IGF-1 remaining above baseline for up to 28 days. While this data relates to the DAC-conjugated form, the pharmacodynamic target, activation of the same GHRH receptor, is identical for the no-DAC variant; the difference is duration and peak amplitude rather than mechanism.
Body Composition and Lean Mass
Elevated GH and IGF-1 exert well-documented effects on body composition in both animal and human models. GH stimulates lipolysis, the mobilization (also referred to as mobilization) of stored triglycerides from adipose tissue for use as an energy substrate. At the same time, IGF-1 drives protein synthesis in skeletal muscle through activation of the PI3K/Akt/mTOR pathway. (6,7) Animal models receiving GHRH analogs show reductions in adiposity and increases in lean tissue mass when administered over multi-week protocols. (8) These findings align with the broader literature on GH-axis restoration in GH-deficient populations, where exogenous GH replacement consistently improves lean-to-fat mass ratios. The distinction worth emphasizing (also spelled emphasizing) for CJC-1295 no DAC is that it achieves GH elevation through endogenous pituitary stimulation rather than exogenous hormone delivery, preserving the feedback-regulated secretory architecture that maintains physiological GH levels between pulses.
Sleep Quality
GHRH has a direct role in regulating non-REM slow-wave sleep, independent of its effects on GH secretion. Intranasal and intravenous administration of GHRH in healthy young men increased both the duration and intensity of slow-wave sleep in controlled studies, with subjects spending significantly more time in stages 3 and 4 sleep than with placebo. (9) This is a bidirectional relationship: the largest physiological GH pulses occur during deep slow-wave sleep, while GHRH itself appears to facilitate entry into and maintenance of these deep sleep stages. Since CJC-1295, no DAC, is a direct structural analog of GHRH, researchers investigating sleep architecture often select it for its ability to stimulate the same receptor pathway without the prolonged systemic exposure associated with the DAC variant. The short half-life makes it particularly suited to evening-administration protocols designed to amplify the natural nocturnal GH surge.
Bone Mineral Density and Tissue Repair
IGF-1 is a key mediator of osteoblast activity and bone matrix formation. Chronic GH deficiency is associated with reduced bone mineral density, and GH replacement therapy in deficient adults consistently improves bone turnover markers. (7) In preclinical fracture-healing models, GH-axis stimulation accelerates callus formation and mineralization. These observations have driven interest in GHRH analogs as research tools for studying musculoskeletal repair timelines and connective tissue remodeling (also spelled remodeling) in controlled experimental settings.
CJC-1295 with DAC vs CJC-1295 no DAC: Key Differences
CJC-1295 with DAC and CJC-1295 no DAC share an identical core peptide sequence, the same four amino acid substitutions, and the same GHRH receptor target. The difference between them is a single structural modification that fundamentally alters pharmacokinetic behavior (also spelled behavior).
CJC-1295 with DAC carries a maleimidopropionic acid (MPA) linker attached to a C-terminal lysine at position 30. Once injected subcutaneously, this reactive group covalently binds to the free cysteine (Cys34) on circulating serum albumin. (2,3) Because albumin has a circulating half-life of approximately 19 days, the conjugated peptide avoids renal filtration and enzymatic clearance for an extended period. The result is a half-life of roughly 6 to 8 days and a sustained, tonic elevation of GH and IGF-1 that persists for well over a week after a single injection. (3)
CJC-1295, no DAC, lacks the MPA-lysine extension entirely. Without albumin binding, the peptide clears from circulation within approximately 30 minutes. (5) This short window produces a sharp, discrete GH pulse followed by a return to baseline, closely replicating the natural pulsatile secretion pattern controlled by the hypothalamic GHRH-somatostatin axis.
The practical distinction matters for researchers designing experimental protocols. The DAC variant provides convenience through less frequent administration but produces a continuous elevation of GH that does not occur under normal physiology. Sustained GH exposure raises theoretical concerns about receptor desensitization (also referred to as desensitization), tachyphylaxis, and disruption of the somatostatin-mediated feedback cycle. (6) The no-DAC variant requires more frequent dosing but preserves the pulse architecture that the pituitary is designed to operate within. For research models aiming to study GH-axis signaling under conditions that approximate natural endocrine function, CJC-1295 no DAC is the more physiologically relevant tool.
CJC-1295 and Ipamorelin: The Synergistic GHRH-GHRP Pairing
CJC-1295, no DAC, and Ipamorelin operate through two distinct receptor systems that converge on the same outcome: a larger, cleaner growth hormone pulse than either peptide produces alone.
CJC-1295 acts at the GHRH receptor on pituitary somatotrophs, amplifying the signal that tells these cells to synthesize and release GH. Ipamorelin acts at the growth hormone secretagogue receptor (GHS-R1a), the same target activated by endogenous ghrelin. Ghrelin-receptor activation triggers GH release through a separate intracellular pathway (phospholipase C and IP3/DAG-mediated calcium mobilization) and also suppresses somatostatin tone, which would otherwise inhibit the GH pulse. (10) When both receptors are activated simultaneously, the GH output is synergistic, exceeding what either stimulus would produce in isolation. (6,10)
Ipamorelin is favored (also spelled favored) over older GHRPs like GHRP-6 and GHRP-2 in pairing protocols due to its selectivity. Ipamorelin stimulates GH release without significant elevation of cortisol, prolactin, or ACTH at standard research doses, a profile that minimizes (also spelled minimizes) confounding variables in experimental designs. (10) GHRP-6, by contrast, produces a pronounced appetite-stimulating effect through ghrelin mimicry, and GHRP-2, while more selective than GHRP-6, still produces measurable cortisol and prolactin increases at higher concentrations.
Healius Peptides offers CJC-1295 and Ipamorelin both as individual research peptides and as a pre-blended formulation. The CJC-1295 + Ipamorelin Blend combines both peptides in a single vial at verified ratios, providing a convenient option for researchers running paired-stimulation protocols. For researchers who need to adjust the ratio of GHRH agonist to GHS agonist independently, purchasing each peptide separately allows precise dose titration for each compound.
CJC-1295 vs Sermorelin vs Tesamorelin: GHRH Analog Comparison
CJC-1295, no DAC, Sermorelin, and Tesamorelin are all synthetic analogs of human GHRH that act at the same pituitary receptor. Still, they differ in their structural modifications, half-lives, regulatory histories, and research applications.
Sermorelin is the unmodified truncated GHRH (1-29) fragment with a C-terminal amide. It retains full receptor-binding activity but is rapidly degraded by DPP-IV, giving it a circulating half-life of under 10 minutes. (1) Sermorelin held FDA approval as Geref for diagnostic and therapeutic use in growth hormone deficiency but was voluntarily withdrawn from the market for commercial reasons, not safety concerns. Its very short half-life makes it useful in acute GH-stimulation tests but limits its utility in sustained research protocols.
CJC-1295 no DAC, as described above, extends sermorelin’s half-life to approximately 30 minutes through four amino acid substitutions that block DPP-IV cleavage. This provides a longer GH-stimulation window without fundamentally altering the pulsatile release profile. Researchers comparing the two in controlled settings typically observe higher peak GH amplitudes with CJC-1295 without DAC at equivalent molar doses, consistent with a longer receptor occupancy before clearance. (1,4)
Tesamorelin is a 44-amino-acid GHRH analog that preserves the native sequence and adds a trans-3-hexenoic acid group to the N-terminus, conferring DPP-IV resistance. It is the only GHRH analog currently holding active FDA approval, marketed as Egrifta SV for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. (11) Its half-life sits between sermorelin and CJC-1295 with DAC, and its clinical evidence base for visceral fat reduction is the strongest of any peptide in this class. For researchers focused on visceral adiposity models, tesamorelin’s published Phase III data offer the most directly translatable reference point.
In summary, sermorelin is the simplest and shortest-acting; CJC-1295, no DAC, is structurally optimized (also spelled optimized) for stability while retaining a short-acting pulsatile profile; and tesamorelin offers the longest clinical track record with active FDA approval. All three are available in the Healius Peptides catalog for researchers selecting GHRH-axis tools appropriate to their specific study design.
References
1. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation, 1989;83(5):1533-1540. Established the DPP-IV cleavage vulnerability of native GHRH and the rationale for amino acid substitutions at positions 2, 8, 15, and 27.
2. Jette L, Lèger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor in the anterior pituitary of rats: identification of CJC-1295 as a long-acting GRF analog. Endocrinology, 2005;146(7):3052-3058. Identified CJC-1295 as a bioconjugate GHRH analog with enhanced DPP-IV resistance and demonstrated GH secretion in cultured rat anterior pituitary cells.
3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhler SA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799-805. Demonstrated 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases in healthy human subjects with dose-dependent effects sustained for 6 to 11 days.
4. Izdebski J, Witkowska E, Kunce D, et al. New potent hGH-RH analogs with increased resistance to enzymatic degradation. Journal of Peptide Science, 2002;8(7):289-296. Characterized tetrasubstituted GRF analogs and their resistance to DPP-IV degradation, establishing the structural basis for Mod GRF 1-29.
5. Sackmann-Sala L, Ding J, Frohman LA, Bhler SA. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in changes in the serum protein profile in normal adult subjects. Growth Hormone & IGF Research, 2009;19(6):471-477. Confirmed the pharmacokinetic distinction between DAC-conjugated and non-DAC forms and the short-acting pulsatile profile of the non-DAC variant.
6. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and humans. Endocrine Reviews, 1998;19(6):717-797. Comprehensive review of the GHRH-somatostatin-GH axis, including receptor signaling, pulsatile secretion patterns, feedback regulation, and the roles of GHS-R1a and GHRH-R.
7. Thomas MJ. The molecular basis of growth hormone action. Growth Hormone & IGF Research, 2001;11(Suppl A): S97-S103. Reviewed downstream GH effects, including lipolysis, protein synthesis, IGF-1 hepatic production, bone mineralization, and tissue repair pathways.
8. Alba M, Fintini D, Bowers CY, Franco C, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology: Endocrinology and Metabolism, 2006;291(6): E1290-E1294. Demonstrated that once-daily CJC-1295 administration restored growth velocity in GHRH-deficient mice, with reduced efficacy at 48- and 72-hour intervals.
9. Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology, 1992;56(4):566-573. Demonstrated GHRH-induced increases in slow-wave sleep duration and intensity in healthy young males.
10. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin is the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552-561. Established ipamorelin’s selective GH-releasing activity without significant cortisol, prolactin, or ACTH elevation, distinguishing it from GHRP-2 and GHRP-6.
11. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357(23):2359-2370. Phase III trial of tesamorelin demonstrating significant reduction in trunk fat in HIV-associated lipodystrophy, forming the basis for FDA approval as Egrifta.
12. ConjuChem Biotechnologies. CJC-1295 clinical program discontinuation. Reported via Wikipedia and regulatory filings. The attending physician attributed the participant’s death to pre-existing asymptomatic coronary artery disease with plaque rupture, unrelated to CJC-1295 treatment.
13. World Anti-Doping Agency. 2025 Prohibited List: International Standard. Section S2.2.4: Growth Hormone Releasing Factors. CJC-1295 is explicitly named alongside CJC-1293, sermorelin, and tesamorelin as prohibited at all times.
Research Use Only Disclaimer
CJC-1295 no DAC (Mod GRF 1-29) is sold by Healius Peptides exclusively for in vitro research and laboratory use. It is not intended for human or veterinary therapeutic use, food, cosmetic, or household application. CJC-1295 no DAC is not a drug, food supplement, or cosmetic product, and it may not be misbranded, misused, or mislabelled as such. By purchasing this product, the buyer acknowledges that it will be used solely for research purposes in accordance with all applicable local, state, national, and international laws and regulations. Healius Peptides assumes no liability for any misuse of this product.
Test Conditions
Primary container: Sealed 3 ml flip-top vial Material at assay: Lyophilised powder, solid state Reconstitution: Tested prior to any reconstitution Sampling method: Drawn directly from the vial, sterile technique
CJC-1295 no DAC (Mod GRF 1-29) Date Tested: February 2, 2026 Purity (HPLC %): 99.96% Mass of Peptide: CJC-1295 no DAC 5.2mg TFA Test: Not Detected Endotoxins (LPS): Pass Sterility: Pass Lot #: HP6648481609-5
Certificates of Analysis
CJC-1295 no DAC (Mod GRF 1-29) 5mg Lab Test Report Feb 2026
CJC-1295 no DAC is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH). It is also known as Mod GRF 1-29. Four amino acid substitutions at positions 2, 8, 15, and 27 provide resistance to enzymatic degradation by DPP-IV, giving it a functional half-life of approximately 30 minutes. It binds to the GHRH receptor on somatotrophs in the anterior pituitary, stimulating pulsatile release of growth hormone. (1,2)
No, CJC-1295 (with or without DAC) is not FDA-approved for any therapeutic indication. CJC-1295 with DAC reached Phase II clinical trials through ConjuChem Biotechnologies, but the program was discontinued. (12) CJC-1295 was nominated for the FDA’s Category 2 bulk drug substance list in September 2023, but the nomination was withdrawn in September 2024 and referred to the Pharmacy Compounding Advisory Committee (PCAC). CJC-1295, no DAC, is sold by Healius Peptides strictly for in vitro research use.
Yes, CJC-1295 without DAC is legal to purchase in the United States for in vitro research purposes. It is not a controlled substance under federal scheduling. Purchasers should ensure their intended use complies with applicable institutional, state, and federal regulations governing research materials.
Yes. CJC-1295 is explicitly named on the World Anti-Doping Agency (WADA) Prohibited List under Section S2.2.4, Growth Hormone Releasing Factors. It is classified alongside other GHRH analogs, including sermorelin and tesamorelin, and is prohibited at all times, both in and out of competition. (13) Any athlete subject to WADA-governed testing who uses CJC-1295 in any form risks a doping violation.
CJC-1295 with DAC includes a Drug Affinity Complex (maleimidopropionic acid-lysine) that binds to serum albumin, extending its half-life to 6 to 8 days and producing a sustained, tonic GH elevation. (3) CJC-1295 without DAC (Mod GRF 1-29) lacks this modification, clears in approximately 30 minutes, and produces short, discrete GH pulses that more closely mirror natural pulsatile secretion patterns. (5)
Mod GRF 1-29 is an alternate name for CJC-1295 without DAC. It refers to a modified version of growth hormone-releasing factor (GRF), specifically the first 29 amino acids, with four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) for enhanced stability. Mod GRF 1-29, CJC-1295 no DAC, and CJC-1295 without DAC all describe the same compound. (1,4)
CJC-1295 without DAC binds to the GHRH receptor on pituitary somatotroph cells, activating a Gs-coupled signaling cascade via adenylyl cyclase, cyclic AMP, and protein kinase A. This drives GH gene transcription and exocytotic release of stored growth hormone. The short half-life of the no-DAC variant means GH is released in a discrete pulse, after which somatostatin feedback restores baseline levels before the next administration. (1,6)
CJC-1295, no DAC, and Ipamorelin target two different receptor systems (GHRH receptor and GHS-R1a, respectively) that produce a synergistic GH-releasing effect when activated simultaneously. (6,10) Healius Peptides offers both compounds individually and as a pre-blended CJC-1295 + Ipamorelin Blend for paired-protocol convenience.
Reported side effects from clinical trials of CJC-1295 (with DAC) include transient injection-site reactions, facial flushing, headache, dizziness, and mild water retention. (3) The no-DAC variant’s shorter systemic exposure may reduce the duration of these effects. CJC-1295 has not undergone long-term safety evaluation in humans, and all use should comply with applicable research regulations.
No. CJC-1295 is a peptide, a short chain of amino acids. It has no structural or functional relationship to anabolic-androgenic steroids. CJC-1295 stimulates pituitary release of growth hormone through the GHRH receptor and does not affect testosterone, estrogen, or other steroid hormone pathways. (6)
Unreconstituted lyophilized CJC-1295 no DAC should be stored at minus 20 degrees Celsius or below for long-term preservation. After reconstitution with bacteriostatic water, store the vial upright in a refrigerator at 2 to 8 degrees Celsius and use within 21 to 28 days. Avoid repeated freeze-thaw cycles.
Yes. CJC-1295 no DAC is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water (BAC water) before use. Inject the BAC water slowly down the inside wall of the vial and swirl gently until the solution is clear. Healius Bacteriostatic Water is available in matched volumes.
Product identity Molecular Weight (g/mol) 3367.94 Peptide Sequence H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 Product Name CJC-1295 no DAC (Mod GRF 1-29) Catalogue Number 5mg CND5 Molecular Formula C152H252N44O42 CAS Number 446036-97-1 Peptide Classification Mod GRF (1-29), short-acting GHRH analogue Lot Number HP6648481609-5 Material profile Active Peptide Compound CJC-1295 no DAC (Mod GRF 1-29) peptide Physical Presentation Sterile lyophilised powder, white to ivory in hue Melting Point Decomposes thermally prior to any melting point Analytical verification Mass Spectrum Molecular Weight Observed mass matches theoretical MW (3367.94 g/mol) Amino Acid Composition Profile Residue ratios match the declared peptide sequence Laboratory use and safety Laboratory Handling Advisory Wear laboratory PPE and follow your institutional safety rules. Authorised Application Strictly in vitro research. No clinical, diagnostic, or veterinary application. GHS Hazard Profile Below GHS hazard thresholds at research-scale quantities Storage and handling protocol Recommended Storage, Post-Opening Hold at minus 20 degrees C; limit freeze-thaw cycles Recommended Storage, Sealed Vial Keep at minus 20 degrees C in the sealed vial Sealed Vial Stability 24 months sealed under recommended storage conditions Reconstituted Solution Stability Holds specification for 28 days at 2 to 8 degrees C under sterile handling Reconstitution Guidance Add bacteriostatic or sterile water down the vial wall. Invert gently until dissolved; do not vortex. Laboratory Handling Notes Protect from light. Return to minus 20 degrees C after aliquoting. Maximum 3 freeze-thaw cycles.
CJC-1295 no DAC
Original price was: $64.95.Current price is: $54.95.
Quantity
from
$49.95
from
$54.95
from
$64.95
from
$89.95
from
$134.95
from
$44.95
from
$199.95
from
$94.95
from
$59.95
from
$49.95
from
$49.95
from
$19.95
from
$54.95
from
$114.95
from
$99.95
from
$69.95
from
$54.95
from
$11.95
from
$49.95
from
$19.95
from
$49.95
from
$54.95
from
$64.95
from
$89.95
from
$134.95
from
$44.95
from
$199.95
from
$94.95
from
$59.95
from
$49.95
from
$49.95
from
$19.95
from
$54.95
from
$114.95
from
$99.95
from
$69.95
from
$54.95
from
$11.95
from
$49.95
from
$19.95
from
$54.95
from
$11.95
from
$49.95
from
$89.95
from
$64.95
from
$69.95
from
$134.95
from
$114.95
from
$19.95
from
$49.95
from
$199.95
from
$134.95
from
$54.95
from
$94.95
from
$59.95
from
$144.95
from
$69.95
from
$19.95
from
$99.95
from
$44.95
from
$54.95
from
$11.95
from
$49.95
from
$89.95
from
$64.95
from
$69.95
from
$134.95
from
$114.95
from
$19.95
from
$49.95
from
$199.95
from
$134.95
from
$54.95
from
$94.95
from
$59.95
from
$144.95
from
$69.95
from
$19.95
from
$99.95
from
$44.95
Join 35,000+ researchers
Subscriber-only pricing, new peptide drops, restock alerts, and fresh lab data delivered before anyone else.